Acquisition Alibaba America Baidu Biotech California China Chinese Hong Kong Investment IPO Online Shopping Pharmaceutical Revenue Search Engine South Korea stock market Technology Venture Capital
Based in San Diego, Axiom Biosciences is set to seek a primary listing in Hong Kong in 2027, followed by a secondary U.S. listing in 2029. The move reflects a growing trend among global biotech firms looking towards Hong Kong for its expanding investor base and close proximity to Chinese pharmaceutical partners, offering potential advantages in trial acceleration and cost reduction. Axiom Biosciences’ decision to list in Hong Kong first, followed by a U.S. listing, diverges from the historical pattern where Chinese companies like Alibaba and Baidu typically opted for U.S. markets. The company’s CEO, Remo Moomiaie-Qajar, sees this move…
News Timeline:
Track the development of this news story across the Internet.